Alan Tan

I didn't do it.

As a community oncologist, I thought it was very bold.

Went to MD Anderson, got an opinion there.

They're like, oh yeah, right on, EV Pembro.

I was like, what?

Yeah.

But he had a complete clinical response and refused radical cystectomy.

And had more of those as well.

And Amanda, you probably have some data from Unite.

All right.

Well, very quickly, we'll just touch a little bit on some precision medicine and metastatic setting, right?

So we know EV302, more than two years ago in Madrid, we saw standing ovation, doubling of overall survival, doubling of PFS, 68% overall response rates, just unprecedented stuff in our lifetime.

So obviously this is transformative data.

And are we curing people with metastatic bladder cancer?

Well, before we get to that, let's just talk about the other elephant in the room here.

We're treating these patients until unacceptable toxicity.

Baseline, you know, our neuropathy is the limiting toxicity for most of these patients, right?

I mean, there are some people that can go on like 20 cycles that like have minimal neuropathy.

I just don't know who these types are, how we cherry pick them.

But yeah, eventually by, you know, six to eight months, people are starting to get grade two neuropathy.